本报记者 包兴安 近日,纳斯达克上市公司——尚高集团与北京欧纳尔生物工程技术有限公司(以下简称“北京欧纳尔生物”)签订了收购框架协议。根据协议,尚高公司将以不高于3000万美元的价格收购北京欧纳尔生物51%以上的股权,共同研发快速抗抑郁天然创新药SNG。最终收购价格,双方将根据第三方机构出具的评估报告具体商定。 北京欧纳尔生物是一家研发天然药物及其衍生产品的生物科技公司,公司董事长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.